Amikura K, Kobari M, Matsuno S
First Department of Surgery, Tohoku University School of Medicine, Sendai, Japan.
Nihon Geka Gakkai Zasshi. 1991 May;92(5):562-6.
By measuring the doubling time both of clinical liver metastases and cultured human pancreatic cancer cell lines, we studied the possibility of occult liver metastases at the time of pancreatectomy in patients with pancreatic cancer. Doubling times of 3 pancreatic cancers were obtained from the measurements of size of liver metastases after pancreatectomy and those were compared with those of cultured human pancreatic cancer cell lines established from two of these cases. Doubling time of liver metastases were about fifteen times as long as those of cultured cell lines. On the assumption that growth rates of liver metastases were constant, the size of liver metastases at the time of pancreatectomy was calculated in three cases. The calculated sizes of these liver metastases were 140 microns, 2.4 mm, and 8.3 mm respectively. These results indicate that occult liver metastases have already existed in patients with pancreatic cancer even though they were clinically undetectable at the time of operation. And some adjuvant therapies against occult liver metastases are necessary for achievement of the better prognosis.
通过测量临床肝转移灶和培养的人胰腺癌细胞系的倍增时间，我们研究了胰腺癌患者行胰十二指肠切除术时存在隐匿性肝转移的可能性。从3例胰腺癌患者胰十二指肠切除术后肝转移灶大小的测量中获取了肝转移灶的倍增时间，并将其与从其中2例患者建立的培养人胰腺癌细胞系的倍增时间进行了比较。肝转移灶的倍增时间约为培养细胞系倍增时间的15倍。假设肝转移灶的生长速率恒定，计算了3例患者胰十二指肠切除术时肝转移灶的大小。这些肝转移灶的计算大小分别为140微米、2.4毫米和8.3毫米。这些结果表明，胰腺癌患者即使在手术时临床上无法检测到，也已经存在隐匿性肝转移。为了获得更好的预后，针对隐匿性肝转移的一些辅助治疗是必要的。
